Fresh off the fast-track designation of its Alzheimer’s disease treatment, Vaxxinity says it will need to secure a partner to take the phase 2-stage neurodegenerative candidate forward.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,